CME: Employing biosimilars in the treatment of inflammatory health conditions: How to and should I?
ACCREDITATION EXPIRED: June 25, 2022
AN ACCREDITED UP-TO-DATE VERSION OF THIS TOPIC CAN BE FOUND AT: Incorporating biosimilars into practice to treat immunologic disease states: Benefits, concerns, and the present treatment landscapeActivity Description / Statement of Need:
In this online, self-learning activity:
Biosimilar drugs are products meant to be similar in quality, safety, and efficacy to an already licensed reference biotherapeutic product. Whereas generics are virtually identical replicas of conventional medications, biosimilars are not the same as the original product – a practically unavoidable outcome because of the considerably large molecular structure that biologics mimic. The literature suggests that learning activities focused on the evolving landscape of biosimilars, which are germane to the therapeutic area because of their potential role in cost containment. Both the FDA and medical literature independently affirm the need for clinician education on biosimilars, including: comparative efficacy; adverse event rates and management (potential concerns have included immunogenicity); regulatory guidance on interchangeability and substitution – including prescribers retaining some degree of ability to intervene in a product’s substitution at the dispensing stage; and cost considerations.
Target Audience:
The following healthcare professionals: Rheumatologists, gastroenterologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with the inflammatory disease states covered by this activity.
Commercial Support Disclosure: This program is supported by educational grants from AMGEN.
This activity is free of charge.
Release Date: June 25, 2020 -- Expiration Date: June 25, 2022
Faculty: Jonathan Kay, MD
Agenda
|
Introduction, disclosures |
|
A primer on biopharmaceuticals vs. small molecules • Characteristic differences in small molecules vs. biologics: Molecular-level differences, composition, method of preparation • Definitions: Biologic, biosimilar, and interchangeability The regulatory landscape • FDA regulation, action, and draft guidance • State laws • Future considerations |
|
A candid assessment of HCP knowledge gaps • Safety issues associated with formulations • Safety issues associated with switching from brand to biosimilar • Prescriber concerns • Potential impact on patient adherence • Counseling patients to use medication safely |
|
The present landscape of treatments for inflammatory conditions · Biosimilar agents approved for the following conditions and related literature review: Inflammatory bowel disease; rheumatological conditions; plaque psoriasis · Efficacy · Safety · Immunogenicity · Patient education: How to discuss biosimilar concepts and options with patients · Patient case(s) |
|
· Future considerations · Summary, conclusion, and recap |
Learning Objectives
By the end of the session the participant will be able to:
- Describe biosimilar drugs, how they differ from generic drugs, the FDA process for their approval.
- Describe practical considerations the clinician needs when determining whether to consider when deciding whether substituting or allowing the substitution of a biosimilar medication for its reference medication, and apply them to patient case(s).
- Describe how biosimilars for inflammatory health conditions are impacting the treatment landscape with respect to number of treatment options, affordability, and safety considerations.
- Identify the currently available and emerging pharmacotherapeutic treatments for management of inflammatory health conditions and apply them to patient cases using evidence-based medicine.
- Describe strategies for helping patients understand the implications of using biosimilars.
Accreditation
ACCME Activity #201861255
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Jonathan Kay, MD, Professor of Medicine and Population and Quantitative Health Sciences,Timothy S. and Elaine L. Peterson Chair in Rheumatology, UMass Memorial Medical Center, University of Massachusetts Medical School, has received compensation as a consultant and/or researcher for Alvotech Suisse AG; Arena Pharmaceuticals; Boehringer Ingelheim; Celltrion Healthcare; Merck Sharp & Dohme; Mylan; Novartis; Samsung Bioepis; Sandoz; UCB; Pfizer; Gilead.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from AMGEN.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Systemic lupus erythematosus: Therapeutic updates and optimizing treatment
Ulcerative Colitis (UC): Optimizing Pharmacotherapeutic Management Strategies
Short bowel syndrome: therapeutic updates and optimizing treatment
Hereditary angioedema (HAE): Optimizing treatment strategies